Venus RemediesBOM:526953 +4.99% Piotroski F-Score is 7 as of Jun. 29, 2026, which is at its 10-year median of 7.00. The stock has 5 warning signs investors should review. Among 978 Drug Manufacturers companies, Venus Remedies ranks better than 91.82% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Venus Remedies has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Venus Remedies's Piotroski F-Score or its related term are showing as below:
BOM:526953'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 7 Max: 8
Current: 7
During the past 13 years, the highest Piotroski F-Score of Venus Remedies was 8. The lowest was 3. And the median was 7.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Venus Remedies Piotroski F-Score Related Terms
Venus Remedies Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Venus Remedies's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:526953 vs ZTS, UTHR: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Venus Remedies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Remedies Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Venus Remedies's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Venus Remedies's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Venus Remedies's current Net Income (TTM) was 1,028.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Venus Remedies's return on assets of this year was 0.14360334. Venus Remedies's return on assets of last year was 0.0722853.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Venus Remedies's current ratio of this year was 2.44312562. Venus Remedies's current ratio of last year was 3.31441294.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Venus Remedies's number of shares in issue this year was 13.367. Venus Remedies's number of shares in issue last year was 13.37.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Venus Remedies's gross margin of this year was 0.49679054. Venus Remedies's gross margin of last year was 0.42008608.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Venus Remedies's asset turnover of this year was 1.07527858. Venus Remedies's asset turnover of last year was 1.0415879.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
0
+
0
+
1
+
1
+
1
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Venus Remedies has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Venus Remedies (BOM:526953) has a Piotroski F-Score of 7 as of Jun. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Venus Remedies and its competitors. This is near median its historical median of 7.00. Over the past decade, Venus Remedies' Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Venus Remedies ranks #80 out of 978 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Venus Remedies' Piotroski F-Score too high?
Venus Remedies' current Piotroski F-Score of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Venus Remedies' value of 7 is 40% above this industry median. Based on the distribution chart, Venus Remedies ranks #80 out of 978 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Venus Remedies' Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Venus Remedies ranks #80 out of 978 companies for Piotroski F-Score. This places Venus Remedies in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Venus Remedies' value of 7 is 40% above this benchmark. Historically, Venus Remedies' own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Venus Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Remedies's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Venus Remedies and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Remedies's current Piotroski F-Score is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (BOM:526953) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹467.09, compared to a current price of ₹1,945.90 — trading 316.6% above its estimated fair value. The current Piotroski F-Score is 7, which is near median its 10-year median of 7.00 and 40% above the Drug Manufacturers industry median of 5.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Venus Remedies (BOM:526953), the current Piotroski F-Score is 7 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526953 has been successfully added to your 